Predictors of treatment response to pharmacotherapy in patients with persistent postural–perceptual dizziness
- 5 February 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Zeitschrift für Neurologie
- Vol. 268 (7), 2523-2532
- https://doi.org/10.1007/s00415-021-10427-7
Abstract
The study aimed to identify the predictors of response to selective serotonin reuptake inhibitors (SSRIs) for 12 weeks in patients with persistent postural–perceptual dizziness (PPPD). Short-term treatment responses were studied in 197 outpatients [127 (64.5%) women, mean age ± SD = 51.7 ± 15.9] diagnosed with PPPD. Clinical and self-rated assessments were analyzed at the baseline and at the end of pharmacotherapy for 12 weeks. Multivariable logistic regression analysis was used to determine the following variables as the potential predictors of treatment response as measured by scoring in clinical global impression-improvement scale (CGI-I) scores: age, sex, comorbidity, baseline CGI-S score, Beck Depression Inventory–II score, State-Trait Anxiety Inventory score, Dizziness Handicap Inventory score at the baseline, and prescribed doses of antidepressants or benzodiazepines. The overall response rate to pharmacotherapy was 65.0% (128/197). Female sex and greater disease severity at the baseline (higher CGI-S score) were associated with a better response to the pharmacotherapy. Subgroup analyses by sex identified younger age and lower anxiety as the indicators for better outcomes in men, and absence of comorbidities in women. During the initial assessment, the severity of PPPD was associated with depressive symptoms and subjective functional handicap due to dizziness. The response to pharmacotherapy is favorable in PPPD. Sex, age and initial disease severity are the predictors of the response to SSRIs in patients with PPPD.Funding Information
- National Research Foundation of Korea (NRF-2020R1A2C1102105)
This publication has 49 references indexed in Scilit:
- Gender differences in anxiety disorders: Prevalence, course of illness, comorbidity and burden of illnessJournal of Psychiatric Research, 2011
- The clinical global impression scale and the influence of patient or staff perspective on outcomeBMC Psychiatry, 2011
- Sex, hormones and neuroeffector mechanismsActa Physiologica, 2010
- Analysis by Age and Sex of Efficacy Data From Placebo-Controlled Trials of Desvenlafaxine in Outpatients With Major Depressive DisorderJournal of Clinical Psychopharmacology, 2010
- Review: Current treatment of vestibular, ocular motor disorders and nystagmusTherapeutic Advances in Neurological Disorders, 2009
- Different gender response to serotonergic and noradrenergic antidepressants. A comparative study of the efficacy of citalopram and reboxetineJournal of Affective Disorders, 2006
- A Prospective Trial of Sertraline for Chronic Subjective DizzinessThe Laryngoscope, 2004
- Screening for depression among neuro-otology patients with and without identifiable vestibular lesions: Identificación de la depresión en pacientes neuro-otológicos con y sin lesiones vestibulares identificablesInternational Journal of Audiology, 2003
- How Important Are Gender Differences in Pharmacokinetics?Clinical Pharmacokinetics, 2002
- Gender Differences in Treatment Response to Sertraline Versus Imipramine in Chronic DepressionAmerican Journal of Psychiatry, 2000